Which agent is used to reduce intracranial pressure in the setting of subarachnoid hemorrhage?

Which agent is used to reduce intracranial pressure in the setting of subarachnoid hemorrhage?

• A. Steroids
• B. Thrombolytics
• C. Warfarin
• D. Mannitol

Answer: (D)

In subarachnoid hemorrhage, quickly lowering intracranial pressure is crucial to prevent further brain injury. Mannitol acts as an osmotic agent that raises plasma osmolality, drawing water out of swollen brain tissue into the bloodstream. This rapid osmotic gradient reduces brain volume and thus lowers intracranial pressure within minutes, which is why it’s commonly used acutely while definitive measures (like securing the aneurysm) are arranged. Use requires IV administration with careful monitoring of osmolality and electrolytes (aim to avoid values that are too high, typically keeping serum osmolality below about 320 mOsm/kg) and renal function, since mannitol can cause dehydration, electrolyte shifts, or kidney strain. It’s important to watch for rebound increases in ICP if administration is stopped abruptly, so it’s titrated and often continued with careful planning. Steroids aren’t effective for reducing intracranial pressure in this setting, and thrombolytics or warfarin would worsen bleeding risk in an intracerebral hemorrhage, making them inappropriate choices here. Mannitol remains a key option for acute ICP management in subarachnoid hemorrhage.

In subarachnoid hemorrhage, quickly lowering intracranial pressure is crucial to prevent further brain injury. Mannitol acts as an osmotic agent that raises plasma osmolality, drawing water out of swollen brain tissue into the bloodstream. This rapid osmotic gradient reduces brain volume and thus lowers intracranial pressure within minutes, which is why it’s commonly used acutely while definitive measures (like securing the aneurysm) are arranged.

Use requires IV administration with careful monitoring of osmolality and electrolytes (aim to avoid values that are too high, typically keeping serum osmolality below about 320 mOsm/kg) and renal function, since mannitol can cause dehydration, electrolyte shifts, or kidney strain. It’s important to watch for rebound increases in ICP if administration is stopped abruptly, so it’s titrated and often continued with careful planning.

Steroids aren’t effective for reducing intracranial pressure in this setting, and thrombolytics or warfarin would worsen bleeding risk in an intracerebral hemorrhage, making them inappropriate choices here. Mannitol remains a key option for acute ICP management in subarachnoid hemorrhage.